SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 45.87-8.6%Feb 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doc Bones who wrote (10195)1/29/2004 1:04:54 PM
From: A.J. Mullen  Read Replies (1) of 52153
 
That's an interesting take on the economics of dual drug combos. I had been assuming the combo would cost more than their component parts - particularly when one is aspirin - and wondered if doctors would explain how patients might save money. A single copay to the insurance company is a powerful incentive for the patient. I suppose insurance companies response will be to put the combo in the tier of drugs that requires the maximum copay.

Ashley
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News